Trial Profile
Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2016
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms DPMCDA
- 14 Dec 2011 Additional trial acronym (DPMCD) identified as reported by ClinicalTrials.gov.
- 27 Oct 2008 Actual patient number (2) added as reported by ClinicalTrials.gov.
- 27 Oct 2008 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.